| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | Adduct of mutually stabilizing menadione and thiamine | EP83105975.3 | 1983-06-18 | EP0098995A1 | 1984-01-25 | Ghelli, Giovanni; Conti, Luciano; Barbon, Alessandro; Oliari, Luigi |
An adduct of menadione and thiamine is described having the general formula C34H36N4O11S3, molecular weight 772,84 and containing the components in a molecular ratio of 2:1 respectively. This adduct is particularly intended to be added to integrator mixtures for zootechny. |
||||||
| 162 | Detergent compositions | US15032199 | 2014-11-03 | US09981933B2 | 2018-05-29 | Matthew Robert Giles |
| A surfactant component comprising a compound of formula (I): (I) wherein R1 is a C5 to C39 alkyl or alkenyl group and R2 is a group of formula (a) wherein one of W, X, Y and Z is a covalent bond and the remaining groups are independently selected from H, M, SO3M and a further group of formula R1CO provided at least one of W, X, Y and Z is SO3M; and each M is independently a hydrogen ion, an ammonium ion or a metal ion. | ||||||
| 163 | Fluoroethyl thiamine or salts thereof and application thereof in preparation of anticoccidial drugs | US14401268 | 2013-03-15 | US09096581B2 | 2015-08-04 | Xianfeng Peng; Zonghua Qin; Qijun Liu |
| The present invention discloses a fluoroethyl thiamine or salts thereof and application thereof in preparation of anticoccidial drugs. The structural formula of the fluoroethyl thiamine or salts thereof is shown as Formula (I). The fluoroethyl thiamine or salts thereof of the present invention have a remarkable anticoccidial effect, particularly on some coccidia which had resistance to other anticoccidial drugs, therefore the fluoroethyl thiamine or salts thereof of the present invention can be applied to preparation of anticoccidial drugs. Thus, the present invention provides conditions for development of new anticoccidial drugs. | ||||||
| 164 | FLUOROETHYL THIAMINE OR SALTS THEREOF AND APPLICATION THEREOF IN PREPARATION OF ANTICOCCIDIAL DRUGS | US14401268 | 2013-03-15 | US20150133480A1 | 2015-05-14 | Xianfeng Peng; Zonghua Qin; Qijun Liu |
| The present invention discloses a fluoroethyl thiamine or salts thereof and application thereof in preparation of anticoccidial drugs. The structural formula of the fluoroethyl thiamine or salts thereof is shown as Formula (I). The fluoroethyl thiamine or salts thereof of the present invention have a remarkable anticoccidial effect, particularly on some coccidia which had resistance to other anticoccidial drugs, therefore the fluoroethyl thiamine or salts thereof of the present invention can be applied to preparation of anticoccidial drugs. Thus, the present invention provides conditions for development of new anticoccidial drugs. | ||||||
| 165 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | US12233906 | 2008-09-19 | US08883783B2 | 2014-11-11 | Shripad S. Bhagwat; Wei Lai; Stephan D. Parent; Melanie J. Roe; Alan Schwartz; Valeriya N. Smolenskaya |
| Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed. | ||||||
| 166 | Compounds for modulating integrin CD11b/CD18 | US12456692 | 2009-06-19 | US08268816B2 | 2012-09-18 | Vineet Gupta; M. Amin Arnaout |
| The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. For example, one such compound useful as an agonist of integrin CD11b/CD18 is the compound of Formula (I): Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | ||||||
| 167 | Fungicide hydroximoyl-tetrazole derivatives | US12309340 | 2007-07-12 | US08119646B2 | 2012-02-21 | Isabelle Christian; Marie-Claire Grosjean-Cournoyer; Pierre Hutin; Philippe Rinolfi; Arounarith Tuch; Jacky Vidal |
| The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituents, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a carbocycle, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | ||||||
| 168 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | US12777902 | 2010-05-11 | US20110110914A1 | 2011-05-12 | Niven Rajin Narain; John Patrick McCook; Rangaprasad Sarangarajan |
| Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | ||||||
| 169 | Carbonyl compounds | US10551557 | 2004-03-08 | US07906516B2 | 2011-03-15 | Christos Tsaklakidis; Dieter Dorsch; Werner Mederski; Bertram Cezanne; Johannes Gleitz |
| Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours. | ||||||
| 170 | Imidazopyridine derivatives useful as iNOS inhibitors | US11886785 | 2006-03-29 | US07790710B2 | 2010-09-07 | Thomas Fuchss; Andreas Strub; Wolf-Rüdiger Ulrich; Christian Hesslinger; Martin Lehner; Raimund Külzer; Rainer Boer; Manfrid Eltze |
| The compounds of formula (I) in which R1, R11 and A have the meanings as given in the description are novel effective iNOS inhibitors. | ||||||
| 171 | Compounds for modulating integrin CD11b/CD18 | US12456692 | 2009-06-19 | US20100056503A1 | 2010-03-04 | Vineet Gupta; M. Amin Arnaout |
| The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency. | ||||||
| 172 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | US12499480 | 2009-07-08 | US20100004254A1 | 2010-01-07 | Qun Sun; Laykea Tafesse; Sam Victory |
| A compound of formula: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Benzoazolylpiperazine Compound are disclosed. | ||||||
| 173 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | US12545954 | 2009-08-24 | US20090312375A1 | 2009-12-17 | David J. Augeri; Jeffrey Bagdanoff; Simon D.P. Baugh; Kenneth G. Carson; Theodore C. Jessop; James E. Tarver |
| Heterocyclic compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I: | ||||||
| 174 | Fungicide hydroximoyl-tetrazole derivatives | US12309338 | 2007-07-12 | US20090291969A1 | 2009-11-26 | Isabelle Christian; Maria-Claire Grosjean-Cournoyer; Pierre Hutin; Philippe Rinolfi; Arounarith Tuch; Jacky Vidal |
| The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituent, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a 5-membered heterocycle, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | ||||||
| 175 | OXIMYL HCV SERINE PROTEASE INHIBITORS | US12328433 | 2008-12-04 | US20090155210A1 | 2009-06-18 | YONGHUA GAI; Yat Sun Or; Zhe Wang |
| The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. | ||||||
| 176 | NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE | US12327245 | 2008-12-03 | US20090149509A1 | 2009-06-11 | Jeffrey JACOBS; Rakesh K. JAIN; Jason G. LEWIS; Dinesh V. PATEL; Zhengyu YUAN |
| N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, salts or prodrugs thereof have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by PDF inhibitors, such as treatment of bacterial infections. | ||||||
| 177 | 2-Pyridinylethylcarboxamide derivatives and their use as Fugicides | US12292676 | 2008-11-24 | US20090088456A1 | 2009-04-02 | Pierre-Yves Coqueron; Philippe Desbordes; Darren James Mansfield; Heiko Rieck; Marie-Claire Grosjean-Cournoyer; Alain Villier; Pierre Genix |
| A compound of general formula (I) A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it. | ||||||
| 178 | Antibacterial agents | US11187708 | 2005-07-22 | US07358359B2 | 2008-04-15 | Niels H. Andersen; Jason Bowman |
| Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds. | ||||||
| 179 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | US10979362 | 2004-11-02 | US07205312B2 | 2007-04-17 | Marc Gaston Venet; Dominique Jean-Pierre Mabire; Jean Fernand Armand Lacrampe; Gerard Charles Sanz |
| The present invention is concerned with compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R1 is hydrogen, hydroxy, C1-6alkyl or aryl; R2 is hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl, optionally substituted pyrrolidinyl or aryl; R3 is hydrogen, optionally substituted C1-6alkyl or aryl; Het is an optionally substituted unsaturated heterocycle selected from imidazolyl, triazolyl, tetrazolyl and pyridinyl; is an optionally substituted unsaturated mono- or bicyclic heterocycle; and aryl is optionally substituted phenyl. The present invention also relates to processes for their preparation and compositions comprising said new compounds, as well as their use as a medicine. | ||||||
| 180 | Treating stress response with chemokine receptor ccr5 modulators | US10501999 | 2003-01-22 | US20050079176A1 | 2005-04-14 | Richard Pierson III; Agnes Azimzadeh; Carsten Schroeder; Julie DeMartino |
| The use of chemokine receptor CCR5 modulators (e.g., CCR5 antagonists) is disclosed for the treatment or prevention of stress response (e.g., fever) in a subject resulting from surgery, infection or other insult to the subject (e.g., a warm-blooded vertebrate). Methods for treating or preventing disorders involving the activation of pro-inflammatory cytokines by administration of a CCR5 modulator, for inhibiting the endogenous production of pro-inflammatory cytokines by the administration of CCR5 modulators, and for determining the efficacy of CCR5 modulators in correcting abnormal levels of pro-inflammatory cytokines are also disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈